Bazlitoran - Idera Pharmaceuticals

Drug Profile

Bazlitoran - Idera Pharmaceuticals

Alternative Names: IMO-8400

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idera Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides; Immunotherapies
  • Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists; Toll-like receptor 9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dermatomyositis
  • Suspended Diffuse large B cell lymphoma; Waldenstrom's macroglobulinaemia
  • No development reported Graft-versus-host disease; Systemic lupus erythematosus
  • Discontinued Duchenne muscular dystrophy; Plaque psoriasis

Most Recent Events

  • 06 Nov 2017 Idera Pharmaceuticals completes enrolment in its phase II trial for Dermatomyositis in USA, Hungary and United Kingdom (NCT02612857)
  • 15 Feb 2017 Idera Pharmaceuticals has patent protection for IMO 8400 in USA and countries outside USA
  • 01 Dec 2016 Idera Pharmaceuticals completes a phase I/II trial in Diffuse large B cell lymphoma (Second-line therapy or greater) in USA (SC) (NCT02252146)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top